Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma

Annals of Oncology ◽

10.1016/j.annonc.2021.05.803 ◽

2021 ◽

Author(s):

K. Shitara ◽

M. Özgüroğlu ◽

Y.-J. Bang ◽

M. Di Bartolomeo ◽

M. Mandalà ◽

...

Keyword(s):

Clinical Outcomes ◽

Open Label ◽

Phase 3 ◽

Molecular Determinants ◽

Open Label Phase ◽

Gastroesophageal Adenocarcinoma

Download Full-text

Response to the letter to the editor for Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma

Annals of Oncology ◽

10.1016/j.annonc.2021.06.027 ◽

2021 ◽

Author(s):

K. Shitara ◽

J. Lunceford

Keyword(s):

Clinical Outcomes ◽

Open Label ◽

Phase 3 ◽

Letter To The Editor ◽

Molecular Determinants ◽

Open Label Phase ◽

Gastroesophageal Adenocarcinoma

Download Full-text

Faculty Opinions recommendation of Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718006635.793477611 ◽

2013 ◽

Author(s):

Ian Beales

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726356324.793557555 ◽

2019 ◽

Author(s):

Jose Biller

Keyword(s):

Acute Stroke ◽

Antiplatelet Therapy ◽

Standard Care ◽

Platelet Transfusion ◽

Cerebral Haemorrhage ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726438889.793525325 ◽

2016 ◽

Author(s):

Stefan Bielack

Keyword(s):

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736682352.793578124 ◽

2020 ◽

Author(s):

Jaffer Ajani

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Oesophageal Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736675072.793566801 ◽

2019 ◽

Author(s):

Pedro Legua Leiva

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Strongyloides Stercoralis ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Superiority Trial ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737782327.793577733 ◽

2020 ◽

Author(s):

Diana English ◽

Andrea Buras

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Randomised Controlled Trial ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00090-5 ◽

2021 ◽

Author(s):

Martin J van den Bent ◽

C Mircea S Tesileanu ◽

Wolfgang Wick ◽

Marc Sanson ◽

Alba Ariela Brandes ◽

...

Keyword(s):

Interim Analysis ◽

Anaplastic Glioma ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30754-3 ◽

2021 ◽

Vol 22 (4) ◽

pp. 499-511 ◽

Cited By ~ 1

Author(s):

Eric P Winer ◽

Oleg Lipatov ◽

Seock-Ah Im ◽

Anthony Goncalves ◽

Eva Muñoz-Couselo ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text